LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO)

Philip Hykin; Sobha Sivaprasad; A. Toby Prevost; Joana Vasconcelos; Caroline Murphy; Joanna Kelly; J.E Brazier; Hasan Basarir; Simon Harding; Yit Yang; Usha Chakravarthy; Andrew J Lotery

LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO)

Philip Hykin
, Sobha Sivaprasad
, A. Toby Prevost
, Joana Vasconcelos
, Caroline Murphy
, Joanna Kelly
, J.E Brazier
, Hasan Basarir
, Simon Harding
, Yit Yang
, Usha Chakravarthy
, Andrew J Lotery

Applied Health Sciences

Research output: Contribution to journal › Article › peer-review

19 Downloads (Pure)

Original language	English
Journal	The Lancet
Publication status	Accepted/In press - 19 May 2016

Cite this

Hykin, P., Sivaprasad, S., Prevost, A. T., Vasconcelos, J., Murphy, C., Kelly, J., Brazier, J. E., Basarir, H., Harding, S., Yang, Y., Chakravarthy, U., & Lotery, A. J. (Accepted/In press). LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO). The Lancet.

Hykin, Philip ; Sivaprasad, Sobha ; Prevost, A. Toby et al. / LEAVO : a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO). In: The Lancet. 2016.

@article{cdf9b96546ce4b798791189a6f3c3bea,

title = "LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO)",

author = "Philip Hykin and Sobha Sivaprasad and Prevost, \{A. Toby\} and Joana Vasconcelos and Caroline Murphy and Joanna Kelly and J.E Brazier and Hasan Basarir and Simon Harding and Yit Yang and Usha Chakravarthy and Lotery, \{Andrew J\}",

year = "2016",

month = may,

day = "19",

language = "English",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

}

Hykin, P, Sivaprasad, S, Prevost, AT, Vasconcelos, J, Murphy, C, Kelly, J, Brazier, JE, Basarir, H, Harding, S, Yang, Y, Chakravarthy, U & Lotery, AJ 2016, 'LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO)', The Lancet.

LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO). / Hykin, Philip; Sivaprasad, Sobha; Prevost, A. Toby et al.
In: The Lancet, 19.05.2016.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - LEAVO

T2 - a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO)

AU - Hykin, Philip

AU - Sivaprasad, Sobha

AU - Prevost, A. Toby

AU - Vasconcelos, Joana

AU - Murphy, Caroline

AU - Kelly, Joanna

AU - Brazier, J.E

AU - Basarir, Hasan

AU - Harding, Simon

AU - Yang, Yit

AU - Chakravarthy, Usha

AU - Lotery, Andrew J

PY - 2016/5/19

Y1 - 2016/5/19

M3 - Article

SN - 0140-6736

JO - The Lancet

JF - The Lancet

ER -

Hykin P, Sivaprasad S, Prevost AT, Vasconcelos J, Murphy C, Kelly J et al. LEAVO: a multicentre phase iii double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO). The Lancet. 2016 May 19.